KR20230074505A - 원하는 특이성을 갖는 이펙터 세포의 제조 방법 - Google Patents

원하는 특이성을 갖는 이펙터 세포의 제조 방법 Download PDF

Info

Publication number
KR20230074505A
KR20230074505A KR1020237012583A KR20237012583A KR20230074505A KR 20230074505 A KR20230074505 A KR 20230074505A KR 1020237012583 A KR1020237012583 A KR 1020237012583A KR 20237012583 A KR20237012583 A KR 20237012583A KR 20230074505 A KR20230074505 A KR 20230074505A
Authority
KR
South Korea
Prior art keywords
cells
gene
cell
tcr
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012583A
Other languages
English (en)
Korean (ko)
Inventor
히로시 가와모토
야스토시 아가타
세이지 나가노
고지 데라다
교코 마스다
겐타 곤도
Original Assignee
고쿠리츠 다이가쿠 호진 교토 다이가쿠
내셔널 유니버시티 코포레이션 쉬가 유니버시티 어브 메디칼 사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠 다이가쿠 호진 교토 다이가쿠, 내셔널 유니버시티 코포레이션 쉬가 유니버시티 어브 메디칼 사이언스 filed Critical 고쿠리츠 다이가쿠 호진 교토 다이가쿠
Publication of KR20230074505A publication Critical patent/KR20230074505A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237012583A 2020-09-24 2021-09-24 원하는 특이성을 갖는 이펙터 세포의 제조 방법 Pending KR20230074505A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-160252 2020-09-24
JP2020160252 2020-09-24
PCT/JP2021/035150 WO2022065444A1 (ja) 2020-09-24 2021-09-24 所望の特異性を有するエフェクター細胞の製造方法

Publications (1)

Publication Number Publication Date
KR20230074505A true KR20230074505A (ko) 2023-05-30

Family

ID=80846656

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012583A Pending KR20230074505A (ko) 2020-09-24 2021-09-24 원하는 특이성을 갖는 이펙터 세포의 제조 방법

Country Status (9)

Country Link
US (1) US20230357715A1 (cg-RX-API-DMAC7.html)
EP (1) EP4219707A4 (cg-RX-API-DMAC7.html)
JP (1) JP7807756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230074505A (cg-RX-API-DMAC7.html)
CN (1) CN116406423A (cg-RX-API-DMAC7.html)
AU (1) AU2021349574A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193384A1 (cg-RX-API-DMAC7.html)
IL (1) IL301534A (cg-RX-API-DMAC7.html)
WO (1) WO2022065444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3822342A4 (en) * 2018-07-13 2022-08-03 Kyoto University METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
WO2016010153A1 (ja) 2014-07-18 2016-01-21 宏 河本 免疫細胞療法用t細胞の誘導方法
WO2016010154A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
WO2017179720A1 (ja) 2016-04-15 2017-10-19 国立大学法人京都大学 Cd8陽性t細胞を誘導する方法
WO2020022512A1 (ja) 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
JP2021525518A (ja) * 2018-05-31 2021-09-27 ワシントン・ユニバーシティWashington University 細胞をゲノム編集及び活性化するための方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010155A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
WO2016010153A1 (ja) 2014-07-18 2016-01-21 宏 河本 免疫細胞療法用t細胞の誘導方法
WO2016010154A1 (ja) 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
WO2017179720A1 (ja) 2016-04-15 2017-10-19 国立大学法人京都大学 Cd8陽性t細胞を誘導する方法
WO2020022512A1 (ja) 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gong Ying et al., Journal of Cell Biology (2015) 1481-1489
Themeli et al., Nat Biotechnol. (2013) 928-33

Also Published As

Publication number Publication date
CN116406423A (zh) 2023-07-07
EP4219707A4 (en) 2024-11-13
EP4219707A1 (en) 2023-08-02
CA3193384A1 (en) 2022-03-31
JPWO2022065444A1 (cg-RX-API-DMAC7.html) 2022-03-31
AU2021349574A1 (en) 2023-05-11
IL301534A (en) 2023-05-01
WO2022065444A1 (ja) 2022-03-31
US20230357715A1 (en) 2023-11-09
JP7807756B2 (ja) 2026-01-28

Similar Documents

Publication Publication Date Title
US12577582B2 (en) Universal donor cells
JP7422365B2 (ja) 外来抗原レセプター遺伝子導入細胞の製造方法
US12427170B2 (en) Universal donor cells
US20230073515A1 (en) Universal donor cells
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
KR20210020873A (ko) 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
US20250134999A1 (en) Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
AU2016379393A1 (en) Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
KR20200001596A (ko) 인위적으로 조작된 조작면역세포
JP2024534720A (ja) 遺伝子改変細胞を作製するための方法
US20220242929A1 (en) Immune cells expressing modified cell receptors and methods of making
AU2022381757A1 (en) Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
Rein et al. Applications of gene editing technologies to cellular therapies
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
US20250000912A1 (en) Hypoimmunogenic stem cells, hypoimmunogenic cells differentiated or derived from stem cells and method of preparing same
CN116887853A (zh) 用于定点诱变的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230413

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination